The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 \[involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic lateral sclerosis (ALS)\] using a new positron emission tomography (PET) tracer called \[18F\]ACI-19626. Both healthy people and people with (suspected) TDP-43 accumulation will participate to this trial. The main questions it aims to answer are: * whether \[18F\]ACI-19626 is safe and well tolerated when injected into participants * whether \[18F\]ACI-19626 reliably detects abnormal TDP-43 in the brain using PET technique. * whether there are differences in the amount of this protein between people with diseases related to TDP-43 accumulation in the brain and people without these diseases. Participants will: * Visit the clinic to consent to their participation and to ensure they are eligible (physical and neurological examinations, questionnaires, blood and urine tests, ECG and MRI in some cases). * Visit the clinic to receive the tracer \[18F\]ACI-19626 intravenously and be scanned in a PET scanner, during which blood will be collected. * Receive a phone call from the clinic 2 to 4 days after the PET scan to report any symptoms and side-effects that they may be having. Some of the participants may be asked to come again to the clinic for a second PET scan, allowing the researchers to determine if the measurements with the first PET scan are stable and reproducible.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with Adverse Events (AEs) assessed by severity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related)
Timeframe: From Informed Consent Signature (screening) to safety phone call after PET scan (i.e. up to 3 months in total)
Number of participants with clinically significant changes in vital signs measurements
Timeframe: During PET scan visit (i.e. at Day 0): before [18F]ACI-19626 injection and after the PET scan is completed
Brain uptake of the tracer [18F]ACI-19626
Timeframe: At the time of the [18F]ACI-19626 PET scan (i.e. at Day 0): 0-90 minutes after injection
Assessment of the optimal kinetic model quantification of [18F]ACI-19626 tracer uptake
Timeframe: At the time of the [18F]ACI-19626 PET scan (i.e. at Day 0): 0-90 minutes after injection
Radiation dosimetry after one [18F]ACI-19626 PET scan
Timeframe: At the time of the [18F]ACI-19626 PET scan (i.e. at Day 0): 0-90 minutes after injection